Chemed (CHE)
(Delayed Data from NYSE)
$538.02 USD
-1.98 (-0.37%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $538.00 -0.02 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Chemed (CHE) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$685.00 | $708.00 | $650.00 | 26.46% |
Price Target
Based on short-term price targets offered by three analysts, the average price target for Chemed comes to $685.00. The forecasts range from a low of $650.00 to a high of $708.00. The average price target represents an increase of 26.46% from the last closing price of $541.68.
Analyst Price Targets (3 )
Broker Rating
Chemed currently has an average brokerage recommendation (ABR) of 1.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by three brokerage firms. The current ABR compares to an ABR of 1.33 a month ago based on three recommendations.
Of the three recommendations deriving the current ABR, two are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 66.67% and 33.33% of all recommendations. A month ago, Strong Buy made up 66.67%, while Buy represented 33.33%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/CHE.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.33 | 1.33 | 1.33 | 1.33 | 1.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/4/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
2/29/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.33 |
ABR (Last week) | 1.33 |
# of Recs in ABR | 3 |
Average Target Price | $685.00 |
LT Growth Rate | 11.30% |
Industry | Medical - Outpatient and Home Healthcare |
Industry Rank by ABR | 33 of 252 |
Current Quarter EPS Est: | 5.54 |